Live chart · TradingView
What it does
Develops treatments that fix or switch off genes. With Vertex, it created Casgevy, the first approved CRISPR therapy, for sickle cell disease and beta thalassemia.
- Ticker
- NASDAQ:CRSP
- Headquarters
- Zug, Suíça
- Founded
- 2013
Evidence Radar
✓ Evidence
- Casgevy approved in the US, UK and EU (2023–2024).
◷ Promises
- Gene editing for cardiovascular disease and cancer.
⚠ What could go wrong
- Slow commercial uptake of expensive, complex therapies.
- Uncertain clinical results.
- Cash burn.
Educational content. Not a recommendation to buy or sell any asset.